GSK

BLENREP

Manufacturer:

GSK

Blenrep HCPCS:

J9037

HCPCS Code Descriptor:

Injection, belantamab mafodotin-blmf, 0.5 mg

Category:

J Code

Blenrep NDCs:

00173-0896-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

00173-0896-01

About Blenrep:

BLENREP is an Oncology drug manufactured by GSK and administered via the Intravenous route of administration. The J Code: J9037 is aligned to the drug BLENREP.

ACCESS PRICING AND MORE BY REGISTERING

J9037 Added Date:

April 1, 2021

J9037 Effective Date:

April 1, 2021

J9037 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Blenrep billing and coding information.
Blenrep patient assistance information can be found through GSK for You at the URL: https://www.gskforyou.com/
BLENREP prescribing information can be found at the link below:
Information regarding BLENREP’s side effects can be found at MedlinePlus